Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The IPI-GLIO trial has opened to recruitment.

This is an unblinded, open labelled stratified randomised Phase II multicentre clinical trial of ipilimumab with temozolomide vs. temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma.

Patients with newly diagnosed de-novo glioblastoma following surgery and radical radiotherapy with concomitant temozolomide will be recruited from 7 sites in the UK, and randomly allocated to receive either ipilimumab and temozolomide or temozolomide alone. The first recruiting site to open is Mount Vernon Cancer Centre in Northwood.

IPI-GLIO is sponsored by the University of Oxford and managed by the Oncology Clinical Trials Office (OCTO). The trial is funded by Bristol-Myers Squibb and The National Brain Appeal. Statistical support is provided by the Centre for Statistics in Medicine (CSM). The Chief Investigator is Dr Paul Mulholland.

Similar stories

WHiTE Four trial results!

OCTRU

The WHiTE Four trial has now published its results in The Bone & Joint journal.

FUTURE GB Trial opens to recruitment!

OCTRU

The FUTURE GB Trial has received OCTRU Green Light approval and is now open to recruitment!

ARCADIAN trial opens to recruitment!

OCTRU

The ARCADIAN trial has received OCTRU Green Light approval and has now begun to open sites to recruitment!

HOPE-e study resumes recruitment of women with painful osteoarthritis in the hand

Main OCTRU

Researchers in Oxford are looking to recruit women who have painful osteoarthritis in joints of their hands, after resuming a study that was paused due to the COVID crisis.

HUSH trial opens to recruitment!

OCTRU

The HUSH trial has received OCTRU Green Light approval and is now open to recruitment!

Oxford researchers start new trial on the use of anti-TNF to treat Covid-19 in care homes

Main OCTRU Trials

Researchers at the University of Oxford are starting a new study to explore the effectiveness of the anti-tumour necrosis factor (anti-TNF) drug adalimumab as a treatment for patients with COVID-19 in the community, especially care homes. The AVID-CC trial, which will be conducted by Oxford Clinical Trials Research Unit (OCTRU), will enrol up to 750 patients from community care settings throughout the UK.